The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
RESOLUTION trial of H. Lundbeck's Vyepti meets all primary, secondary endpoints (DKK 37.00, 0.00)
SUNRISE trial of H. Lundbeck's Vyepti meets all primary, secondary endpoints (DKK 37.00, 0.00)
Powered by FactSet Research Systems Inc.